

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptaul53cxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

|              |    |         |  |
|--------------|----|---------|--|
| NEWS         | 1  |         | Web Page URLs for STN Seminar Schedule - N. America  |
| NEWS         | 2  |         | "Ask CAS" for self-help around the clock   |
| NEWS         | 3  | May 12  | EXTEND option available in structure searching   |
| NEWS         | 4  | May 12  | Polymer links for the POLYLINK command completed in REGISTRY   |
| NEWS         | 5  | May 27  | New UPM (Update Code Maximum) field for more efficient patent SDIs in Cplus  |
| NEWS         | 6  | May 27  | Cplus super roles and document types searchable in REGISTRY  |
| NEWS         | 7  | Jun 28  | Additional enzyme-catalyzed reactions added to CASREACT  |
| NEWS         | 8  | Jun 28  | ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)   |
| NEWS         | 9  | Jul 12  | BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS   |
| NEWS         | 10 | Jul 30  | BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting  |
| NEWS         | 11 | AUG 02  | IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields   |
| NEWS         | 12 | AUG 02  | Cplus and CA patent records enhanced with European and Japan Patent Office Classifications   |
| NEWS         | 13 | AUG 02  | STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting  |
| NEWS         | 14 | AUG 02  | The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available  |
| NEWS         | 15 | AUG 04  | Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004                          |
| NEWS EXPRESS |    | JULY 30 | CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004 |
| NEWS HOURS   |    |         | STN Operating Hours Plus Help Desk Availability  |
| NEWS INTER   |    |         | General Internet Information   |
| NEWS LOGIN   |    |         | Welcome Banner and News Items  |
| NEWS PHONE   |    |         | Direct Dial and Telecommunication Network Access to STN  |
| NEWS WWW     |    |         | CAS World Wide Web Site (general information)  |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 17:22:43 ON 06 AUG 2004

|  |            |       |
|--|------------|-------|
| => file caplus uspatful japio europatful medline biosis embase scisearch |            |       |
| COST IN U.S. DOLLARS   | SINCE FILE | TOTAL |

|                     |       |         |
|---------------------|-------|---------|
|                     | ENTRY | SESSION |
| FULL ESTIMATED COST | 0.21  | 0.21    |

FILE 'CAPLUS' ENTERED AT 17:23:12 ON 06 AUG 2004  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 17:23:12 ON 06 AUG 2004  
 CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 17:23:12 ON 06 AUG 2004  
 COPYRIGHT (C) 2004 Japanese Patent Office (JPO)- JAPIO

FILE 'EUROPATFULL' ENTERED AT 17:23:12 ON 06 AUG 2004  
 COPYRIGHT (c) 2004 WILA Verlag Muenchen (WILA)

FILE 'MEDLINE' ENTERED AT 17:23:12 ON 06 AUG 2004

FILE 'BIOSIS' ENTERED AT 17:23:12 ON 06 AUG 2004  
 COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 17:23:12 ON 06 AUG 2004  
 COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 17:23:12 ON 06 AUG 2004  
 COPYRIGHT 2004 THOMSON ISI

=> s (mucosal? or transmucosal?) and aqueous?  
 L1 17170 (MUCOSAL? OR TRANSMUCOSAL?) AND AQUEOUS?

=> s ((osmotic pressure) or osmolarity)  
 L2 79047 ((OSMOTIC PRESSURE) OR OSMOLARITY)

=> s l1 and l2  
 L3 1205 L1 AND L2

=> s l3 and mOsm  
 L4 204 L3 AND MOSM

=> s l4 and (290 mOsm)  
 L5 6 L4 AND (290 MOSM)

=> d l5 1-6 ibib abs

L5 ANSWER 1 OF 6 USPATFULL on STN  
 ACCESSION NUMBER: 2003:89399 USPATFULL  
 TITLE: Non-peptide inhibition of T-lymphocyte activation and  
 therapies related thereto  
 INVENTOR(S): Chandy, K. George, Laguna Beach, CA, United States  
 Wulff; Heike, Irvine, CA, United States  
 Cahalan, Michael D., Laguna Beach, CA, United States  
 Grismer, Stephan, Blaustein, GERMANY, FEDERAL REPUBLIC  
 OF  
 Rauer, Heiko J., Irvine, CA, United States  
 Miller, Mark J., Brea, CA, United States  
 PATENT ASSIGNEE(S): The Regents of the University of California, Oakland,  
 CA, United States (U.S. corporation)

|                     | NUMBER         | KIND | DATE         |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 6541494     | B1   | 20030401     |
| APPLICATION INFO.:  | US 2000-479391 |      | 20000106 (9) |
| DOCUMENT TYPE:      | Utility        |      |              |
| FILE SEGMENT:       | GRANTED        |      |              |

PRIMARY EXAMINER: Travers, Russell  
LEGAL REPRESENTATIVE: Buyan, Robert D., Stout, Uxa, Buyan & Mullins, LLP  
NUMBER OF CLAIMS: 11  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)  
LINE COUNT: 1387

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds, preparations and methods for immunosuppressive treatment of autoimmune disorders, graft rejection and/or graft/host disease. Therapeutically effective amounts of certain substituted triarylmethane compounds, such as 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole, are administered to mammalian patients to selectively inhibit the calcium-activated K<sup>sup.+</sup> channel (IKCa1) in lymphocytes, monocytes, macrophages, platelets or endothelial cells without concomitant inhibition of P450-dependent enzyme systems, resulting in reduction of antigen-, cytokine-, or mitogen-induced calcium entry through store operated calcium channels in these cells, suppression of cytokine production by these cells, and inhibition of activation of these cells. Such inhibition of the Ca<sup>sup.++</sup> activated K<sup>sup.+</sup> channel (IKCa1) prevents the pre-Ca<sup>sup.++</sup> stage of cell activation and thus causes immunosuppression and an anti-inflammatory response.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2002:295175 USPATFULL  
TITLE: Mediators of hedgehog signaling pathways, compositions and uses related thereto  
INVENTOR(S): Baxter, Anthony David, Hertfordshire, UNITED KINGDOM  
Boyd, Edward Andrew, Oxfordshire, UNITED KINGDOM  
Guicherit, Oivin M., Belmont, MA, UNITED STATES  
Price, Stephen, Buckinghamshire, UNITED KINGDOM  
Rubin, Lee L., Wellesley, MA, UNITED STATES

|                     | NUMBER         | KIND | DATE         |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 2002165221  | A1   | 20021107     |
| APPLICATION INFO.:  | US 2001-977096 | A1   | 20011012 (9) |

|                       | NUMBER  | DATE          |
|-----------------------|---|---------------|
| PRIORITY INFORMATION: | US 2000-240536P   | 20001013 (60) |
|                       | US 2000-240564P   | 20001013 (60) |
| DOCUMENT TYPE:        | Utility   |               |
| FILE SEGMENT:         | APPLICATION   |               |
| LEGAL REPRESENTATIVE: | ROPES & GRAY, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624 |               |
| NUMBER OF CLAIMS:     | 92  |               |
| EXEMPLARY CLAIM:      | 1   |               |
| NUMBER OF DRAWINGS:   | 58 Drawing Page(s)  |               |
| LINE COUNT:           | 5140  |               |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2002:105654 USPATFULL  
TITLE: Nicotine mucosal spray

INVENTOR(S): Jones, Richard L., Edmonton, CANADA

|                     | NUMBER         | KIND | DATE         |
|---------------------|----------------|------|--------------|
| PATENT INFORMATION: | US 2002054856  | A1   | 20020509     |
|                     | US 6596740     | B2   | 20030722     |
| APPLICATION INFO.:  | US 2001-983554 | A1   | 20011024 (9) |

|                       | NUMBER   | DATE          |
|-----------------------|--|---------------|
| PRIORITY INFORMATION: | US 2000-243205P  | 20001024 (60) |
| DOCUMENT TYPE:        | Utility  |               |
| FILE SEGMENT:         | APPLICATION  |               |
| LEGAL REPRESENTATIVE: | Anita Nador, Bereskin & Parr, 40 King Street West, Box 401, Toronto, ON, M5H 3Y2 |               |
| NUMBER OF CLAIMS:     | 20   |               |
| EXEMPLARY CLAIM:      | 1  |               |
| NUMBER OF DRAWINGS:   | 5 Drawing Page(s)  |               |
| LINE COUNT:           | 737  |               |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A composition for administration to the nasal mucosa of a subject comprises a solution of nicotine or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable solvent. The composition has a nicotine concentration less than 10 mg/ml. The composition used alone assists in reduction of the desire of a subject to smoke tobacco. It also reduces the nasal symptoms associated with administration of higher concentrations of nicotine to the nasal mucosa.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 6 USPATFULL on STN

ACCESSION NUMBER: 93:7131 USPATFULL  
TITLE: Treatment of osmotic disturbance with organic osmolytes  
INVENTOR(S): Gullans, Steven R., Natick, MA, United States  
Heilig, Charles W., Needham, MA, United States  
PATENT ASSIGNEE(S): Brigham and Women's Hospital, Boston, MA, United States (U.S. corporation)

|                       | NUMBER   | KIND | DATE         |
|-----------------------|--|------|--------------|
| PATENT INFORMATION:   | US 5182299   |      | 19930126     |
| APPLICATION INFO.:    | US 1991-670779   |      | 19910319 (7) |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 1990-495575, filed on 19 Mar 1990, now abandoned |      |              |
| DOCUMENT TYPE:        | Utility  |      |              |
| FILE SEGMENT:         | Granted  |      |              |
| PRIMARY EXAMINER:     | Raymond, Richard L.  |      |              |
| ASSISTANT EXAMINER:   | Hollinden, Gary E.   |      |              |
| LEGAL REPRESENTATIVE: | Sterne, Kessler, Goldstein & Fox   |      |              |
| NUMBER OF CLAIMS:     | 14   |      |              |
| EXEMPLARY CLAIM:      | 1  |      |              |
| NUMBER OF DRAWINGS:   | 26 Drawing Figure(s); 23 Drawing Page(s)   |      |              |
| LINE COUNT:           | 2185   |      |              |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of treating an osmotic disturbance in an animal which comprises administering to an animal an effective amount of an organic osmolyte, wherein the organic osmolyte is a polyol. Specific polyols include myo-inositol and sorbitol. Also included are precursors of organic osmolytes including precursors of polyols. Other polyol precursors are selected from the group consisting of glucose, glucose polymers, and glycerol. Also inclu

This invention was funded by a research grant from the National Institutes of Health, 1R01 DK36031, which provides to the United States Government certain rights in the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 6 JAPIO (C) 2004 JPO on STN  
ACCESSION NUMBER: 2004-099624 JAPIO  
TITLE: MEDICINAL COMPOSITION FOR ADMINISTRATION TO MUCOSA  
INVENTOR: NISHIBE YOSHIHISA; KINOSHITA WATARU; KAWABE HIROYUKI  
PATENT ASSIGNEE(S): TEIJIN LTD  
PATENT INFORMATION:

| PATENT NO     | KIND | DATE     | ERA    | MAIN IPC   |
|---------------|------|----------|--------|------------|
| JP 2004099624 | A    | 20040402 | Heisei | A61K009-10 |

APPLICATION INFORMATION

STN FORMAT: JP 2003-430651 20031225  
ORIGINAL: JP2003430651 Heisei  
PRIORITY APPLN. INFO.: JP 1998-110887 19980421  
PRIORITY APPLN. INFO.: JP 1998-110888 19980421  
SOURCE: PATENT ABSTRACTS OF JAPAN (CD-ROM), Unexamined  
Applications, Vol. 2004

AN 2004-099624 JAPIO

AB PROBLEM TO BE SOLVED: To provide a new medicinal composition for  
administration to mucosa and having low **osmotic pressure**

SOLUTION: The medicinal composition for administration to mucosa and for  
application to pharmacotherapy comprises a water-insoluble and/or slightly  
water-soluble material and an **aqueous** medium and has less than  
**290 mOsm osmotic pressure**. The  
composition has superior transitivity in blood to conventional medicinal  
compositions for administration to musca. And a composition for  
administration to mucosa, comprising a hemostatic agent and a medicament,  
is provided. The composition has superior osmosis and retention in the  
**mucosal** tissue to the conventional medicinal compositions.  
COPYRIGHT: (C)2004,JPO

L5 ANSWER 6 OF 6 EUROPATFULL COPYRIGHT 2004 WILA on STN

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 619729 EUROPATFULL EW 199928 FS PS  
TITLE: COMPOSITION TO HELP STOP SMOKING.  
ZUSAMMENSETZUNG ZUR RAUCHERENTWOEHNUNG.  
COMPOSITION ET PROCEDE DE SUPPLEANCE AU TABAGISME.  
INVENTOR(S): JONES, Richard, L., 10928 - 81 Street, Edmonton, Alberta  
T5H 1L5, CA  
PATENT ASSIGNEE(S): Pharmacia & Upjohn Aktiebolag, 112 87 Stockholm, SE  
PATENT ASSIGNEE NO: 1720686  
AGENT: Bannerman, David Gardner et al, Withers & Rogers,  
Goldings House, 2 Hays Lane, London SE1 2HW, GB  
AGENT NUMBER: 28001  
OTHER SOURCE: EPB1999039 EP 0619729 B1 990714  
SOURCE: Wila-EPS-1999-H28-T1  
DOCUMENT TYPE: Patent  
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch  
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R  
IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE  
PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale  
Anmeldung)

PATENT INFORMATION:

|                      | PATENT NO      | KIND DATE   |
|----------------------|----------------|-------------|
|                      | EP 619729      | B1 19990714 |
| 'OFFENLEGUNGS' DATE: |                | 19941019    |
| APPLICATION INFO.:   | EP 1993-901989 | 19930104    |

PRIORITY APPLN. INFO.: GB 1992-47 19920103  
 RELATED DOC. INFO.: WO 93-CA3 930104 INTAKZ  
 WO 9312764 930708 INTPNR  
 REFERENCE PAT. INFO.: DE 3241437 A GB 2030862 A  
 GB 2133691 A US 4920989 A  
 US 4953572 A  
 REF. NON-PATENT-LIT.: DATABASE WPIL Week 8414, Derwent Publications Ltd.,  
 London, GB; AN 84-086173 (14)

=> d 15 3 HIT

L5 ANSWER 3 OF 6 USPATFULL on STN

TI Nicotine mucosal spray

SUMM [0002] The invention relates to the field of nicotine mucosal sprays, to compositions comprising nicotine that can be administered in a mucosal spray form and to methods and uses therefore. In one embodiment, the invention relates to compositions and methods useful for subjects who wish to reduce tobacco smoking.

DETD [0030] The term "pharmaceutically acceptable solven." means a solvent that is physiologically tolerable at the dosage administered. Nicotine is soluble in water but an aqueous solvent should have it's pH adjusted with buffers and it's osmolarity adjusted into the physiological range. Those skilled in the art will know how to accomplish these adjustments.

DETD [0035] It is desirable that nasal administration of nicotine provides a sufficient dose of nicotine to a sufficiently large area of the nasal mucosa to give the desired rapid increase in blood nicotine level without providing a local nicotine concentration so high that it causes mucosal irritation and without requiring the delivery of such a large volume of nicotine-containing composition that a portion of the administered dose runs from the nose, causing annoyance and inconvenience to the user.

DETD [0052] Five concentrations of NNS were prepared from base solution containing 10 mg/ml nicotine. The (-) isomer of nicotine (the naturally occurring form) was obtained from Sigma-Aldrich Canada Ltd (Oakville, ON, Cat# N3876). To make the 10 mg/ml nicotine solution, 1 gm of nicotine was dissolved in 100 ml phosphate-buffered saline. Phosphate-buffered saline (PBS) was prepared by adding 0.71 gm Na.sub.2HPO.sub.4 and 0.69 gm Na.sub.2HPO.sub.4 to sterile distilled H.sub.2O to make 10 ml. Then 0.92 gm NaCl was added. The resulting solution had a pH of 6.8 and a 1 osmolarity of 290 mOsm. The five lower nicotine concentrations contained 9, 7, 5, 3 and 1 mg/ml of nicotine. The 9 mg/ml solution was prepared by diluting 18 ml of the base solution (10 mg/ml) with 2 ml PBS. The 7 mg/ml solution contained 14 ml of the base solution and 6 ml of PBS, the 5 mg/ml solution contained 14 ml of the base solution and 14 ml PBS, the 3 mg/ml solution contained 6 ml of the base solution and 14 ml PBS and the 1 mg/ml solution contained 2 ml of the base and 18 ml PBS. The viscosity of the solutions was near 1.0 cps (similar to water).

=> d his

(FILE 'HOME' ENTERED AT 17:22:43 ON 06 AUG 2004)

FILE 'CAPLUS, USPATFULL, JAPIO, EUROPATFULL, MEDLINE, BIOSIS, EMBASE, SCISEARCH' ENTERED AT 17:23:12 ON 06 AUG 2004

L1 17170 S (MUCOSAL? OR TRANSMUCOSAL?) AND AQUEOUS?  
 L2 79047 S ((OSMOTIC PRESSURE) OR OSMOLARITY)  
 L3 1205 S L1 AND L2  
 L4 204 S L3 AND MOSM  
 L5 6 S L4 AND (290 MOSM)

=> s l4 and bioavailability  
L6 135 L4 AND BIOAVAILABILITY

=> s l6 and hypotonic?  
L7 4 L6 AND HYPOTONIC?

=> d l7 1-4 ibib abs

L7 ANSWER 1 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2003:194115 USPATFULL  
TITLE: Monobactam compositions and methods of use thereof  
INVENTOR(S): Shawar, Ribhi M., Bellevue, WA, UNITED STATES

|                     | NUMBER         | KIND | DATE          |
|---------------------|----------------|------|---------------|
| PATENT INFORMATION: | US 2003133925  | A1   | 20030717      |
| APPLICATION INFO.:  | US 2002-256341 | A1   | 20020926 (10) |

|                       | NUMBER   | DATE          |
|-----------------------|--|---------------|
| PRIORITY INFORMATION: | US 2001-325933P  | 20010928 (60) |
| DOCUMENT TYPE:        | Utility  |               |
| FILE SEGMENT:         | APPLICATION  |               |
| LEGAL REPRESENTATIVE: | Chiron Corporation, Intellectual Property, P.O. Box 8097, Emeryville, CA, 94662-8097 |               |
| NUMBER OF CLAIMS:     | 15   |               |
| EXEMPLARY CLAIM:      | 1  |               |
| NUMBER OF DRAWINGS:   | 4 Drawing Page(s)  |               |
| LINE COUNT:           | 849  |               |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods, compounds and compositions are provided for inhibiting the growth of pathogenic microbes in vitro and of treatment of pathogenic bacterial infections in vivo using an antibacterial monobactam compound and a mucolytic agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 2 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2003:187438 USPATFULL  
TITLE: Topical formulations of natamycin/pimaricin  
INVENTOR(S): Andersson, Borje S., Houston, TX, UNITED STATES  
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System (U.S. corporation)

|                     | NUMBER         | KIND | DATE          |
|---------------------|----------------|------|---------------|
| PATENT INFORMATION: | US 2003129225  | A1   | 20030710      |
| APPLICATION INFO.:  | US 2002-294491 | A1   | 20021114 (10) |

|                       | NUMBER   | DATE          |
|-----------------------|--|---------------|
| PRIORITY INFORMATION: | US 2001-332806P  | 20011114 (60) |
| DOCUMENT TYPE:        | Utility  |               |
| FILE SEGMENT:         | APPLICATION  |               |
| LEGAL REPRESENTATIVE: | FULBRIGHT & JAWORSKI L.L.P., A REGISTERED LIMITED LIABILITY PARTNERSHIP, 600 CONGRESS AVENUE, SUITE 2400, AUSTIN, TX, 78701-3271 |               |
| NUMBER OF CLAIMS:     | 36   |               |
| EXEMPLARY CLAIM:      | 1  |               |
| NUMBER OF DRAWINGS:   | 1 Drawing Page(s)  |               |
| LINE COUNT:           | 1498   |               |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to formulations of Pimaricin (also called Natamycin), that are useful for the treatment and suppression of topical infections such as those caused by various pathogens including molds and

yeast, that are resistant to azole compounds and to Amphotericin B.  
Methods for treatment of infections are also set forth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2002:192071 USPATFULL  
TITLE: FORMULATED NUCLEIC ACID COMPOSITIONS AND METHODS OF  
ADMINISTERING THE SAME FOR GENE THERAPY  
INVENTOR(S): ROLLAND, ALAIN, THE WOODLAND, TX, UNITED STATES  
MUMPER, RUSSELL J., THE WOODLAND, TX, UNITED STATES

|                       | NUMBER  | KIND | DATE         |
|-----------------------|---|------|--------------|
| PATENT INFORMATION:   | US 2002103142   | A1   | 20020801     |
|                       | US 6514947  | B2   | 20030204     |
| APPLICATION INFO.:    | US 1997-798974  | A1   | 19970211 (8) |
| DOCUMENT TYPE:        | Utility   |      |              |
| FILE SEGMENT:         | APPLICATION   |      |              |
| LEGAL REPRESENTATIVE: | LYON & LYON LLP/ VALENTIS INC., 633 WEST FIFTH STREET,<br>SUITE 4700, LOS ANGELES, CA, 90071-2066 |      |              |
| NUMBER OF CLAIMS:     | 55  |      |              |
| EXEMPLARY CLAIM:      | 1   |      |              |
| NUMBER OF DRAWINGS:   | 11 Drawing Page(s)  |      |              |
| LINE COUNT:           | 2413  |      |              |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for administering nucleic acid compositions in vitro to cells in culture or in vivo to an organism whereby the uptake of nucleic acids is enhanced are provided. Various compositions, including those incorporating protective, interactive, non-condensing compounds, are utilized to protect and administered nucleic acid formulation, thereby prolonging the localized bioavailability of the administered nucleic acid and enhancing expression from the nucleic acid.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2002:119301 USPATFULL  
TITLE: Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis  
INVENTOR(S): Osbakken, Robert S., Camarillo, CA, UNITED STATES  
Hale, Mary Anne, Woodland Hills, CA, UNITED STATES  
Leivo, Frederick T., Carpinteria, CA, UNITED STATES  
Munk, James D., Camarillo, CA, UNITED STATES

|                       | NUMBER  | KIND | DATE         |
|-----------------------|---|------|--------------|
| PATENT INFORMATION:   | US 2002061281   | A1   | 20020523     |
| APPLICATION INFO.:    | US 2001-942959  | A1   | 20010831 (9) |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. WO 2000-US18410, filed on 5 Jul 2000, UNKNOWN Continuation-in-part of Ser. No. US 2000-577623, filed on 25 May 2000, PENDING |      |              |

|                       | NUMBER          | DATE          |
|-----------------------|-----------------|---------------|
| PRIORITY INFORMATION: | US 1999-142618P | 19990706 (60) |
|                       | US 1999-142620P | 19990706 (60) |
|                       | US 1999-142621P | 19990706 (60) |
|                       | US 1999-142622P | 19990706 (60) |
|                       | US 1999-142624P | 19990706 (60) |
|                       | US 1999-142741P | 19990706 (60) |
|                       | US 1999-142881P | 19990706 (60) |
|                       | US 2000-193507P | 20000403 (60) |
|                       | US 2000-193508P | 20000403 (60) |



US 2000-193509P 20000403 (60)  
US 2000-193510P 20000403 (60)  
US 2000-194078P 20000403 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: MORGAN, LEWIS & BOCKIUS, 1800 M STREET NW, WASHINGTON,  
DC, 20036-5869

NUMBER OF CLAIMS: 37  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 1 Drawing Page(s)  
LINE COUNT: 1893

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutical compositions are described that comprise one or more active ingredients selected from the group consisting of an anti-infective agent, anti-inflammatory agent, anti-mucolytic agent, antihistamine, an antiseptic, and antibiotic combinations or combinations of others of these classes of ingredients, and particularly to compositions formulated as a solution or suspension in a unit dose for aerosol administration to treat chronic sinusitis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>